<SEC-DOCUMENT>0001104659-25-011849.txt : 20250212
<SEC-HEADER>0001104659-25-011849.hdr.sgml : 20250212
<ACCEPTANCE-DATETIME>20250212080214
ACCESSION NUMBER:		0001104659-25-011849
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250212
DATE AS OF CHANGE:		20250212

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OS Therapies Inc
		CENTRAL INDEX KEY:			0001795091
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				825118368
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94604
		FILM NUMBER:		25612067

	BUSINESS ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		410-297-7793

	MAIL ADDRESS:	
		STREET 1:		15825 SHADY GROVE ROAD
		STREET 2:		SUITE 135
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OS THERAPIES Inc
		DATE OF NAME CHANGE:	20191125

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SATTERFIELD THOMAS A JR
		CENTRAL INDEX KEY:			0001132317
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		2609 CALDWELL MILL LN
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35243
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001104659-24-094008</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SATTERFIELD THOMAS A JR -->
          <cik>0001132317</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001795091</issuerCik>
        <issuerName>OS Therapies Incorporated</issuerName>
        <issuerCusip>68764Y207</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>115 Pullman Crossing Road, Suite 103</com:street1>
          <com:city>Grasonvile</com:city>
          <com:stateOrCountry>MD</com:stateOrCountry>
          <com:zipCode>21638</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>61215.00</soleVotingPower>
        <sharedVotingPower>1206250.00</sharedVotingPower>
        <soleDispositivePower>61215.00</soleDispositivePower>
        <sharedDispositivePower>1206250.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>1267465.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.9</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>* Based on 21,238,378 shares of common stock of the issuer outstanding as of November 11, 2024, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024. In addition to 954,965 shares of common stock, the Reporting Person may be deemed to beneficially own 156,250 units ("Units"), with each Unit being comprised of (i) one share of the issuer's Series A Senior Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock"), convertible into shares of the issuer's common stock based upon the conversion ratio set forth in the applicable Certificate of Designation (initially on a one-for-one basis, subject to adjustment) and (ii) a warrant to purchase one share of common stock (the "Warrants"), at an initial exercise price of $4.40 per share (subject to adjustment). This assumes the conversion of the Units that the Reporting Person may be deemed to beneficially own, including the conversion of the underlying Series A Preferred Stock into common stock and the exercise of the underlying Warrants.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>OS Therapies Incorporated</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>115 Pullman Crossing Road, Suite 103, Grasonvile, MD 21638</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Thomas A. Satterfield, Jr.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>15 Colley Cove Drive
Gulf Breeze, Florida 32561</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Incorporated by reference from Item 4 of the Cover Page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Incorporated by reference from Item 9 of the Cover Page.</amountBeneficiallyOwned>
        <classPercent>Incorporated by reference from Item 11 of the Cover Page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Incorporated by reference from Item 5 of the Cover Page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Incorporated by reference from Item 6 of the Cover Page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Incorporated by reference from Item 7 of the Cover Page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Incorporated by reference from Item 8 of the Cover Page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 100,000 shares issuable upon the conversion of the Units (as defined on the Cover Page) are held by Tomsat Investment &amp; Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 162,500 shares issuable upon the conversion of the Units are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and 943,750 shares are held by Satterfield Vintage Investments, L.P. Tomsat Investment &amp; Trading Co., Inc. and A.G. Family L.P. jointly own a majority of Satterfield Vintage Investments, L.P.'s equity, and Tomsat Investment &amp; Trading Co., Inc. is the general partner of Satterfield Vintage Investments, L.P.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas A. Satterfield, Jr.</signature>
        <title>Thomas A. Satterfield, Jr.</title>
        <date>02/12/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
